安进

350.42
开盘价
352.72
市值
190.44B+
最高价
352.72
最低价
348.39
收盘价
NaN
成交量
47.17K+
市盈率
24.83
股息率
2.69%

安进简介

安进公司是一家生物技术公司,主要从事人用创新药物的探索、研发、生产和销售,致力于造福患有严重疾病的患者,释放生物学潜力。其产品包括以下品牌:Aranesp, BLINCYTO, Corlanor, ENBREL, EPOGEN, IMLYGIC, KYPROLIS, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, XGEVA。公司于1980年4月8日由William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld创立,总部位于加州千橡树市。自从1980年创始以来,安进公司已经成长为全球领先的独立生物技术公司之一,为全球数百万患者提供创新药物,同时拥有一批极具潜力的在研药物。

如何购买 安进 (AMGN)

登录
1分钟开户

1分钟开户

仅需1分钟即可完成账户申请和验证。整个过程完全自助,支持 RockFlow App 和网页端操作。

充值资金

充值资金

账户验证完成后,您可以使用首选的支付方式向账户充值。

购买 AMGN

购买 AMGN

通过 RockFlow App 或网页端搜索 AMGN,输入您想要投资的金额,然后点击确认即可完成交易。

logo

Social

Download

google playapp store

© Rockalpha Limited. All Rights Reserved.

Rockalpha Limited is registered on the New Zealand Financial Service Providers Register(FSP: 1001454). Rockalpha Limited's Financial Service Providers registration can be verified on the Financial Service Providers Register. Rockalpha Limited is a member of the Insurance & Financial Services Ombudsman Scheme, an independent dispute resolution service provider. Rockalpha Limited is not licensed by a New Zealand regulator to provide the client money or property services, and Rockalpha Limited’s registration on the New Zealand register of financial service providers or membership of the Insurance & Financial Services Ombudsman Scheme does not mean that Rockalpha Limited is subject to active regulation or oversight by a New Zealand regulator.Rockalpha Limited is registered on the New Zealand Financial Service Providers Register(FSP: 1001454). Rockalpha Limited's Financial Service Providers registration can be verified on the Financial Service Providers Register. Rockalpha Limited is a member of the Insurance & Financial Services Ombudsman Scheme, an independent dispute resolution service provider.